Pharmacological Characterization of a Novel Complement C3 Inhibitor Antibody Fragment.
The antibody fragment shows promise as a potent C3 inhibitor with specific activity across complement pathways, but its clinical implications remain to be determined.
Where it sits
this study against the rest of the olatorepatide corpusSummary and findings
This study characterized a novel complement C3 inhibitor antibody fragment in preclinical settings. The antibody fragment demonstrated high affinity for C3 ligands and dose-dependent inhibition of membrane attack complex formation. Notably, the half-maximal inhibitory concentrations (IC50) were reported as 79 nM for the classical pathway, 344 nM for the alternative pathway, and 67 nM for the lectin pathway.
Abstract
<h4>Introduction</h4>The complement system is a key driver of geographic atrophy (GA), a disease that leads to progressive, irreversible vision loss. Pharmacological preclinical studies characterizing an antibody fragment, which is a novel complement C3 inhibitor under investigation for GA treatment, are presented.<h4>Methods</h4>Kinetic parameters were determined for the antibody fragment binding to C3, C3b, and C3 variants associated with GA. Inhibition of membrane attack complex (MAC) formation after classical (CP), alternative (AP), and lectin (LP) pathway activation was determined. Comparisons with the second-generation compstatin derivative (APL-1) were made because of the expected similarity of binding behavior and in vitro potency with pegcetacoplan (which could not be sourced at the time of the study). Diffusion through Bruch's membrane (BrM) was investigated for the antibody fragment and a pegcetacoplan-similar (PEG-s) molecule using enriched porcine BrM in Ussing chamber devices.<h4>Results</h4>The antibody fragment showed high (picomolar) affinity for all tested C3 ligands. APL-1 showed lower (single-digit nanomolar) affinity than the antibody fragment, comparable with published values. The antibody fragment exhibited dose-dependent inhibition of MAC formation via CP (half-maximal inhibitory concentration [IC<sub>50</sub>] 79 nM), AP (344 nM), and LP (67 nM), with enhanced potency for inhibiting CP- and LP-mediated complement activation vs. APL-1. More efficient permeation of the BrM was observed with the antibody fragment than with the PEG-s molecule.<h4>Conclusion</h4>The antibody fragment is a potent and specific C3 inhibitor that displays dose-dependent inhibition of MAC formation across all three complement pathways and effectively crosses the BrM. In line with these results, the antibody fragment is being investigated in patients with GA. Graphical abstract available for this article.
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
Not reported in abstract.